Nextstellis vs. Estradiol: Key Compositional and Clinical Differences
Nextstellis is fundamentally different from estradiol because it is a combined oral contraceptive containing both drospirenone (3 mg, a progestin) and estetrol (14.2 mg, a novel estrogen), whereas estradiol is a single-component natural estrogen used primarily for hormone replacement therapy, not contraception. 1
Composition and Mechanism
Nextstellis Components:
- Contains estetrol (E4), a plant-synthesized fetal estrogen with unique selective tissue activity
- Combined with drospirenone (DRSP), a fourth-generation progestin with anti-mineralocorticoid and anti-androgenic properties 2
- Formulated as 24 active tablets plus 4 placebo tablets in a 28-day cycle 1
Estradiol:
- Single-component natural estrogen (17-β-estradiol)
- Used alone or combined with progestins for menopausal hormone therapy, not as standalone contraception 3
Indications
Nextstellis is FDA-approved specifically for contraception in females of reproductive potential 1. The combination works synergistically to prevent pregnancy primarily through ovulation inhibition 4.
Estradiol alone is indicated for menopausal symptoms (hot flashes, vaginal atrophy) and osteoporosis prevention—not for contraception 3.
Important Limitation:
Nextstellis may be less effective in females with BMI ≥30 kg/m², with decreasing effectiveness as BMI increases 1.
Cardiovascular and Thrombotic Risk Profile
Nextstellis Advantages:
The estetrol component in Nextstellis demonstrates significantly reduced thrombotic risk compared to traditional combined oral contraceptives containing ethinyl estradiol 5, 6:
- Minimal impact on coagulation factors: E4/DRSP shows considerably less effect on protein S, antithrombin, and tissue factor pathway inhibitor compared to ethinyl estradiol-containing pills 6
- Lower thrombin generation: Approximately 4-fold less increase in thrombin generation (measured by activated protein C sensitivity ratio) versus ethinyl estradiol/drospirenone 6
- Reduced D-dimer elevation: 4.7-fold lower D-dimer levels compared to ethinyl estradiol formulations 6
- No venous thromboembolism events reported in phase 3 trials 7
This contrasts sharply with traditional combined oral contraceptives containing ethinyl estradiol and drospirenone, which carry a VTE risk of approximately 10 per 10,000 woman-years—50-80% higher than levonorgestrel-containing pills 2.
Blood Pressure Effects:
Drospirenone's anti-mineralocorticoid activity provides unique cardiovascular benefits 8:
- Nextstellis shows no significant blood pressure changes in normotensive women 9, 5
- May actually decrease blood pressure in hypertensive women (12.5 mmHg systolic, 9.4 mmHg diastolic reduction observed with similar formulations) 8
- This contrasts with traditional combined oral contraceptives containing ethinyl estradiol, which typically increase blood pressure 9
Metabolic Effects
Nextstellis demonstrates favorable metabolic profiles 10, 4:
- Decreased triglyceride and cholesterol levels with drospirenone-only and natural estrogen combinations 10
- No clinically significant effects on glucose metabolism 11
- Ethinyl estradiol, by contrast, induces various pro-coagulatory factors and metabolic alterations 12
Bleeding Profile and Tolerability
Nextstellis provides predictable, regular bleeding patterns 7, 11:
- Scheduled bleeding occurs in 82.9-87.0% of cycles with median duration of 4.5 days 7
- Unscheduled bleeding decreases from 30.3% in Cycle 1 to 15.5-19.2% by later cycles 7
- Most common adverse events: headache (5.0%) and metrorrhagia (4.6%) 7
- Discontinuation rate for adverse events: 7.1% 7
Contraindications Specific to Nextstellis
Nextstellis has specific contraindications not applicable to estradiol alone 1:
- Renal impairment (due to drospirenone's anti-mineralocorticoid effects and hyperkalemia risk)
- Adrenal insufficiency
- High risk of arterial/venous thrombotic disease
- Smoking in women over age 35
- Co-administration with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir
Critical Monitoring:
Check serum potassium during the first treatment cycle in women on long-term medications that may increase potassium (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, heparin) 1.
Clinical Bottom Line
Nextstellis represents a fundamentally different medication class than estradiol alone—it is a combined hormonal contraceptive with a novel estrogen (estetrol) that demonstrates reduced thrombotic risk compared to traditional ethinyl estradiol-containing pills, while estradiol is a single-component hormone used for menopausal therapy. The addition of drospirenone provides contraceptive efficacy, anti-androgenic benefits, and potential cardiovascular advantages through anti-mineralocorticoid activity 10, 5, 11.